Samsung Biologics Rights Offering Draws 11.44 Trillion Won in Subscription Deposits
Samsung Biologics’ general public offering for its 2.7-trillion-won, or approximately $2.02 billion, rights offering attracted more than 11 trillion won in subscription deposits, demonstrating strong market demand. The result marks the largest amount on record among rights offerings that proceeded t
We haven't written up this one. BusinessKorea has the full story — the link below goes straight to it.